Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | +25.00% | 0.00% | 0.00% |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Mar. 05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
Business Summary
Number of employees: 4
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Clinical-stage Life Sciences
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 20-07-12 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Corporate Secretary | - | 21-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 20-10-21 | |
Thian Chew
CEO | Chief Executive Officer | - | 17-11-30 |
Alan Yamashita
BRD | Director/Board Member | 74 | 19-02-11 |
Rob Merriel
BRD | Director/Board Member | - | 20-08-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,421,632,206 | 3,271,816,919 ( 50.95 %) | 0 | 50.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
0.00% | 17.12M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.09% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- IVX Stock
- Company Invion Limited